News

Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis

Regulatory 60/100How we got 60/100Source tierSpecialist communityTier ceiling60/100Independent sourcesnot recordedPublished score60/100Scored at the ceiling for a specialist community source — it cannot go higher. The number is the source page’s own score, hard-capped at the tier ceiling; corroboration is recorded but cannot lift a score past that cap. Under 40 a claim goes to review instead of publication. Full methodology →
July 31, 2026↗ source

The FDA has granted accelerated approval to Novo Nordisk’s Wegovy (semaglutide) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. This decision is based on Phase 3 data from the ESSENCE trial, where the drug significantly outperformed placebo in resolving liver inflammation and improving scarring. Wegovy is now the first GLP-1 receptor agonist approved for this liver condition.

Related peptides

SemaglutideGlucagon-Like Peptide-1GLP-1GlucagonGLP-1 receptor agonistGLP-1RAGLP-1 RAGLP1-raKE peptideGLP-1R
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.